Antimicrobial Resistance Diagnostics Market Size & Share 2024 to 2032

Antimicrobial Resistance Diagnostics Market Size

The global antimicrobial resistance diagnostics market was valued at USD 4.4 billion in 2023 and is estimated to grow at a CAGR of over 6.3% from 2024 to 2032. The global market for diagnosing antimicrobial resistance is rapidly expanding because of the spread of antibiotic-resistant infections, the growing need for precision medicine, and increasing advancement in diagnostics technology.

For instance, according to the CDC, 2.8 million people in the U.S. afflicted with antibiotic-resistant infections, leading to over 36,500 deaths each year. The rising threat from these numbers increasing the demand for effective diagnostics to monitor infections leading to market growth.
 

The development of molecular diagnostics, immunoassays, and next-generation sequencing (NGS) have considerably heightened the accuracy and pace at which resistance is detected and diagnosed. For example, molecular diagnostics' accuracy makes them widely popular and readily accepted. In addition, antimicrobial resistance (AMR) has steadily emerged as an important area of concern for governments and health organizations globally, which subsequently leads to funding and efforts to improve diagnostic detection. In the U.S., for example, the National Action Plan combating antibiotic-resistant bacteria focuses on the need for rapid diagnostic testing.
 

AMR poses the most considerable threat to treatment and prevention against a constantly expanding spectrum of infections from bacteria, parasites, viruses, and fungi. Tests done quickly on sites of infections do not only help in identifying the presence of antimicrobial-resistant bacteria, assessing its susceptibility, and differentiating between viral or bacterial infections. They also help in effective treatment and in epidemiological surveillance because emerging resistant infective agents and their transmission can be tracked.
 

Antimicrobial Resistance Diagnostic Market Trends

Emerging advanced technologies in the field of diagnostics, like polymerase chain reaction (PCR) and next-generation sequencing, have made it possible to find resistant bacteria's primary site of infection quickly and accurately. Consequently, these advancements are expected to significantly contribute to the growth of the AMR diagnostic market. Additionally, the rising trend in point-of-care testing captures immediate action and facilitates faster treatment options. This would significantly increase the market needs for AMR diagnostics, thus leading to market growth.
 

For example, Sysmex Corporation introduced a testing system in June 2023 in the European market, which is used for testing the presence of bacteria. The system tests urine samples from people who are suspected of having UTIs to check for the presence of bacteria and determine the effectiveness of the antimicrobial agent. Thus, the rising infectious disease incidents, growing public knowledge, and advancing technologies along with favorable government policies and increasing focus on personalized medicine are propelling the market growth.
 

Antimicrobial Resistance Diagnostic Market Analysis

Based on product type, the market is segmented into kits & reagents, and instruments & consumables. The kits & reagents segment dominated the market with USD 2.8 billion in 2023.
 

• The detection of AMR involves identifying the resistant strains of bacteria with precision and speed, which is made possible by kits and reagents. Timely diagnosis is critical in routing the right treatment at the early stages, which prevents the misuse of antibiotics responsible for fostering resistance.
   
• The demand for AMR diagnostic kits and reagents is further propelled by international and national campaigns. For instance, the World Health Organization's Global Antimicrobial Resistance Surveillance System (GLASS) that seeks to collate and report AMR data worldwide to devise appropriate action plans targeted toward different regions.
   
• These initiatives lead to greater demand for uniform diagnostic measures to enhance the comparability of health outcomes across different regions and health systems.

Learn more about the key segments shaping this market

Download Free PDF

Based on technology, the antimicrobial resistance diagnostic market is bifurcated into microbiology culture, immunoassay, polymerase chain reaction (PCR), next generation sequencing (NGS), mass spectrometry, rapid & point of care, and other technologies. The microbiology culture segment accounted for significant market share of 31.1% in 2023.
 

• Advances in technology on microbial culture have drastically improved the speed, accuracy, and specificity of resistant strain detection. Diagnoses are now done in hours instead of days due to faster automated culture system platforms such as the BD Phoenix or Vitek.
   
• Moreover, the increasing trends indicate a favorable environment for culture-based diagnostics of antibiotic-resistant bacteria, which in turn increases the expected growth of the market.
   
• Furthermore, AMR will lead to increased infections among the elderly and together with comorbidities poses risk to the economy with a potential global GDP loss reaching USD 100 trillion by 2050.
   
• Thus, the accurate diagnosis and use of appropriate microbiology cultures is crucial in the management of infection prevention and control costs that stem from resistant infections.
   
• These diagnostic devices improve the effectiveness of treatment and prevent additional time being spent in the hospital, saving costs associated with AMR.
   

Based on pathogen type, the antimicrobial resistance diagnostic market is divided into drug-resistant streptococcus pneumoniae (DRSP), drug-resistant campylobacter (DRC), clostridium difficile (CD), drug-resistant Neisseria gonorrhoeae (DRNG), and other pathogen types. The clostridium difficile segment is expected to reach USD 2.3 billion by 2032.
 

• C. Difficile is one of the most predominant causes of HAIs and mostly occurs in hospitalized patients and aged individuals. Comorbidities enable more elderly patients which means that infection rates are increasing. The CDC estimates that there are around 500,000 C. difficile infections each year in the U.S., with 20% of these patients becoming reinfected.
   
• Moreover, new technologies such as next-generation sequencing (NGS) and AI-based diagnostics are rapidly emerging that will help to better characterize the strains and resistance of C. difficile. Even though these new technologies are still at their initial stage, they tend to improve the diagnostic accuracy and understanding of the epidemiology of infections.
   

Based on end use, the antimicrobial resistance diagnostic market is divided into hospitals & clinics, diagnostic laboratories, pharmaceutical & biotechnology companies, and other end users. The hospitals & clinics segment dominated the market with USD 1.8 billion in 2023.
 

• Given that there is a high possibility of encountering resistant pathogens, hospitals and clinics are the main locations for AMR testing. Around 1 in 31 inpatients in the U.S. suffers from HAIs, which increases the necessity for AMR diagnostics for these infections significantly.
   
• At the same time, there particularly is a high number of diagnostic tests carried out in hospitals which fuels the need for faster and more precise AMR diagnostics kits. Point-of-care testing and rapid testing in hospitals allow healthcare professionals to start treatment faster and prevent the further spread of resistant infections.

U.S. antimicrobial resistance diagnostic market is expected to grow at 6.2% CAGR, to reach USD 3.1 billion by the end of 2032.
 

• The U.S. government has launched the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB) and the Antibiotic Resistance Solutions Initiative (ARSI) to address AMR.
   
• CARB strives to enhance AMR diagnostic capabilities with high-throughput technologies and provides funds and grants to firms and academic institutions which boost the industry.
   
• Moreover, the secretary of the U.S. Department of Health and Human Services (HHS) has made considerable commitments to funding AMR research, diagnostics, and new antibiotic development.
   
• The CDC's AR Lab Network has received more regional funding which helps with market growth for AMR pathogens in 2023.
   

Germany antimicrobial resistance diagnostic market is experiencing robust growth in the European market.
 

• There is mounting evidence that Germany's AMR problem is worsening regarding cases that have bacterial pathogens such as Escherichia coli or Staphylococcus aureus, and Klebsiella pneumoniae.
   
• In addition, Germany has increase expenditure associated with AMR infections. Annual healthcare-associated infections stemming from resistant pathogens result in extra health expenditure costs of USD 1.5 million per year, thus accelerating market growth.
   

The Asia Pacific antimicrobial resistance diagnostic market is witnessing substantial growth of 6.8% during the analysis period.
 

• Healthcare reforms by the government of China aim at increasing the availability and affordability for diagnostics product, facilitates expansion of the AMR diagnostics market through initiatives like the Healthy China 2030.
   
• Furthermore, China is also starting to use more advanced molecular diagnostics methods like PCR and next-generation sequencing (NGS) methods that allow fast and accurate detection of AMR strains, which helps in boosting the market.
   

The Brazil market is experiencing robust growth in Latin America.
 

• Brazil's National Action Plan on AMR contains provisions on surveillance of antimicrobial use and resistance, including compulsory registration and data sharing within the healthcare system.
   
• Moreover, as per the data from the Association of Diagnostic Medicine from Brazil, yearly infections diagnostic tests are growing annually by 30% due to the demand for immediate detection of resistant pathogens.
   

The Saudi Arabia antimicrobial resistance diagnostic market is witnessing substantial growth during the analysis period.
 

• The complemented regulatory strategies, together with the public health campaigns by the Saudi government, show the commitment towards AMR. Market growth is being propelled by the emphasis placed by many health authorities on the need for detecting and intervening antibiotic resistance.
   
• Furthermore, the increased efforts by a wider segment of the healthcare professionals, government agencies, and the public towards raising standards of antibiotic use and awareness over the need for accurate and timely AMR diagnosis is driving prospects.
   
• There is also an increase in educational campaigns that encourage restriction of antibiotic use and better diagnostic methods, thereby contributing to market growth.
   

Antimicrobial Resistance Diagnostic Market Share

The global market for diagnosis of antimicrobial resistance has many competing suppliers and therefore, the manufacturers seek ways to respond to the existing AMR challenge. Leading enterprises provide comprehensive diagnostic products, for example molecular diagnosis and point-of-care (POC) diagnostics. They spend large amounts of capital on getting the best measurement reporting units in the lowest time, along with the highest number of identified pathogens. Also, the formation of alliances between companies for strategic collaboration is much easier because they can capitalize on NGS, and other PCR based diagnostic kits and expand their products. Moreover, emerging market players are concentrating on the Asia Pacific and Latin American regions where demand for AMR diagnostics is increasing as government spending on healthcare infrastructure expansion rises. In addition to this, governmental policies and funding allow for the creation of more effective AMR diagnostic tools.
 

Antimicrobial Resistance Diagnostic Market Companies

Prominent players operating in the antimicrobial resistance diagnostic industry include:

• Abbott Laboratories
• Accelerated Diagnostics, USA
• Alifax
• Bio-Rad Laboratories
• BioMerieux
• Beckman Coulter
• Becton, Dickinson and Company
• F. Hoffmann-La Roche
• GeneFluidics
• Molsid
• Thermo Fisher Scientific
• Vela Diagnostics
   
• Comprehensive portfolio of cutting-edge diagnostic tools to identify resistance pathogens
• Regulatory compliance with global standards
• Customizable solutions to specific healthcare settings such as hospitals and diagnostic laboratories
   

Antimicrobial Resistance Diagnostic Industry News:

• In In October 2024, FIND and the Kingdom of Saudi Arabia announced the convening of a high-level side event focused on closing gaps in diagnostics to prevent AMR. This initiative aims to tackle AMR and is expected to expand the organization's reach into untapped economies.
   
• In July 2022, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, along with the life sciences company Evotec SE and bioMérieux, announced a joint venture to develop the next generation of antimicrobials and actionable diagnostics to combat AMR. This collaboration helped the company broaden its product offerings for AMR diagnosis.
   

The antimicrobial resistance diagnostic market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Kits & reagents
• Instruments & consumables

Market, By Technology

• Microbiology culture
• Immunoassay
• Polymerase chain reaction (PCR)
• Next generation sequencing (NGS)
• Mass spectrometry
• Rapid & point of care
• Other technologies

Market, By Pathogen Type

• Drug-resistant streptococcus pneumoniae (DRSP)
• Drug-resistant campylobacter (DRC)
• Clostridium difficile (CD)
• Drug-resistant Neisseria gonorrhoeae (DRNG)
• Other pathogen types

Market, By End Use

• Hospitals & clinics
• Diagnostic laboratories
• Pharmaceutical & biotechnology companies
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE